Exelixis announces results from analysis of CABINET Phase 3 trial of CABOMETYX

Exelixis (EXEL) announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX versus placebo in patients with previously treated advanced neuroendocrine tumors, NET, originating in the lungs or thymus. These data will be presented at the 2025 European Society for Medical Oncology Congress, ESMO, on October 20, 2025. In the phase 3 CABINET study, patients with locally advanced or metastatic pancreatic NET, pNET, or extra-pancreatic NET, epNET, were randomized 2:1 in separate cohorts to receive CABOMETYX 60 mg daily versus placebo. Patients with epNET had tumors arising in the gastrointestinal tract, lung, rare sites including the thymus and unknown primary sites. Of the 203 patients in the epNET cohort, 49 had lung or thymic NET. With a median follow-up for progression-free survival, PFS, of 5.5 months, CABOMETYX reduced the risk of disease progression or death by 81% versus placebo. Median PFS was 8.2 months with CABOMETYX compared to 2.7 months with placebo. Confirmed objective response rates were 6% versus 0%, respectively.